These studies propose that the effect may be dose-dependent and that hypertension might be indicative of effective VEGF inhibition and a positive antiangiogenic response, and as such could be a biomarker of a favorable outcome from VSP inhibitors treatment. This evidence concerns the gene VEGFA and Hypertension.